24/7 Market News Snapshot 28 January, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

January 28, 2025

DENVER, Colo., 28 January, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp is witnessing a significant surge in market activity, with shares climbing to $1.116, reflecting an impressive increase of 92.41% since the previous session’s close of $0.580. With trading volume reaching approximately 24.92 million shares, there is a palpable sense of investor enthusiasm and market confidence in the company’s potential for growth. This upward trend suggests that Silexion is breaking through previous resistance levels, generating intrigue among traders about future developments for the company.

In conjunction with this market reaction, Silexion has recently revealed groundbreaking preclinical data for its promising therapeutic candidate, SIL-204. This siRNA treatment targets KRAS-driven cancers, addressing a critical area of need in oncology. The preclinical findings indicate that SIL-204 effectively reduces tumor growth in pancreatic cancer models, particularly in tumors harboring the KRAS G12D mutation, achieving a remarkable 50% reduction over a 30-day period. Notably, around 50% of the treated tumors showed complete necrosis, reinforcing SIL-204’s efficacy.

Dr. Mitchell Shirvan, Chief Scientific Officer of Silexion, expressed optimism regarding the data, emphasizing the compound’s potential to alter treatment approaches for aggressive cancers like pancreatic cancer. The study demonstrated that a single systemic administration of SIL-204 maintains effective drug concentrations for over 56 days, thereby ensuring sustained therapeutic activity.

With ongoing research and a commitment to innovative cancer therapies, Silexion is poised to establish itself as a significant player in the biotechnology landscape. The company aims to further broaden its development strategies for KRAS-driven cancers, with plans for future announcements to detail these advancements. The combination of robust market activity and promising clinical data positions Silexion as a key player in the continuous pursuit of effective cancer treatments.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.